April 23, 2025

Measles-Mumps vaccine loses effectiveness at 7 & 17 years


Mayo Clinic Vaccine Research, HHS, MD
Source: Vaccine, Feb 2013

View ONLINE or Download PDF

A large and significant decrease in measles and mumps IgG titers (antibodies) was found when testing individuals 7 and 17 years after two-dose MMR vaccination. This suggests measles protection from vaccination is not lifetime. The researchers stated the suspected reason for the decline is secondary vaccine failure.

ABSTRACT
The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-IIĀ® vaccination, in a cohort of 98 healthy adults.

Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles.